Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · IEX Real-Time Price · USD
9.18
-0.25 (-2.70%)
Jul 22, 2024, 12:04 PM EDT - Market open
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 76 employees as of December 31, 2023. The number of employees decreased by 7 or -8.43% compared to the previous year.
Employees
76
Change (1Y)
-7
Growth (1Y)
-8.43%
Revenue / Employee
$90,171
Profits / Employee
-$1,821,276
Market Cap
922.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76 | -7 | -8.43% |
Dec 31, 2022 | 83 | -7 | -7.78% |
Dec 31, 2021 | 90 | - | - |
Related Stocks
Company Name | Employees |
---|---|
HealthStream | 1,092 |
CareDx | 643 |
BioLife Solutions | 414 |
Bicycle Therapeutics | 284 |
AnaptysBio | 117 |
Silence Therapeutics | 109 |
Viridian Therapeutics | 94 |
Pharvaris | 82 |
CNTA News
- 6 weeks ago - Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and - GlobeNewsWire